These findings suggest PPAR alpha could be a therapeutic target for reducing Abeta burden in AD (Corbett et al., 2015), especially as PPAR alpha exerts powerful anti-inflammatory effects and Wnt/beta-catenin activation upregulates PPAR alpha expression (Kozinski and Dobrzyn, 2013). This evidence concerns the gene APP and Alzheimer disease.